- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00133601
Cognitive Behavioral Therapy for Insomnia in Chronic Pain Patients
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Forty five subjects, both male and female, of diverse racial backgrounds, ages >25 with insomnia secondary to pain will be recruited from the Pain Clinic at URMC and from the community at large via advertisements and solicited primary care referrals to participate in a parallel-groups, randomized, single blind, controlled trial. Protocol eligible subjects (as determined via a phone screen interview or by responses to our web based screening questionnaire) will be evaluated in-lab. The screen will determine whether subjects have chronic insomnia secondary to pain and do not meet any of the exclusion criteria. Once found to be study eligible, they are given an appointment for the reading and signing of the consent and the intake interview. The in-lab intake interview includes the administration of a broad battery of self-report instruments. Following the clinical interview, subjects will undergo a physical exam. The history (to include drug and ETOH use) and physical examination will include blood and urine chemistries to rule out any acute or unstable medical co-morbidity (including pregnancy). The lab work will include profiles to assess renal, liver, thyroid, and anemia as well as urine toxicology screen for illicit drug use. The lab work results will be reviewed by the Co-PI and our medical consultant. If significant abnormal findings are discovered, the subject will be referred to their primary care provider for treatment. In addition to conducting an "in-house" physical, after the subject signs a release of information, the researchers also FAX the prospective subject's primary care physician a letter asking them to confirm that the individual is eligible for the study.
If data from both these evaluations suggest that the subject is protocol eligible, according to the inclusion and exclusion criteria, the subject is asked to fill out two weeks of sleep/pain diaries. The diary data are used to "prospectively" confirm the severity and frequency of the subjects sleep complaints and as baseline data. Finally, all subjects will be evaluated by polysomnography (PSG) to assure that they do not have an occult sleep disorder. Once determined to be study appropriate, the subjects will be randomized into a treatment group. They will see the therapist weekly for 8 weeks. At 3 month and 6 month intervals after weekly therapy session end, the subject will be asked to fill out sleep diaries and wear an actiwatch for a period of two weeks.
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
New York
-
Rochester, New York, États-Unis, 14642
- University of Rochester Neurophysiology and Sleep Research Laboratory
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Ages eligible for Study: Over 25 years of age
- Chronic pain (>6 months) in the neck and back that has been diagnosed by a physician
- Insomnia (>30 minutes to get to sleep, >30 minutes wake during the night and daytime loss of function due to insomnia and pain)
Exclusion Criteria:
- Unstable medical problems
- Currently undergoing surgery or procedures for their pain or medical problems
- Head injuries
- Seizure disorders
- Taking sleeping pills
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Aucune intervention: 2
Groupe de contrôle
|
|
Expérimental: 1
CBT-1
|
CBT-I including sleep restriction, stimulus control, sleep hygiene instructions and one session of cognitive therapy devoted to catastrophic thoughts about the consequences of insomnia.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
To determine and confirm "prospectively" the severity and frequency of the subjects sleep complaints and as baseline data.
Délai: 8 weeks
|
8 weeks
|
Collaborateurs et enquêteurs
Collaborateurs
Les enquêteurs
- Chercheur principal: Michael Perlis, PhD, University of Rochester
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 9080
- 5R21NR009080-02 (Subvention/contrat des NIH des États-Unis)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur La douleur chronique
-
Evergrain, LLCINQUIS Clinical Research Ltd.ComplétéSatiété du pain riche en fibres et riche en protéinesCanada
-
Tel-Aviv Sourasky Medical CenterWeizmann Institute of ScienceComplétéChangements de poids corporel | Modification alimentaire | Microbiote gastro-intestinal | Pain | Tests hématologiquesIsraël
-
University of BergenUniversity of Leipzig; Chalmers University of Technology; Nofima; Paderborn UniversityComplétéHyperglycémie | Prédiabète | Contrôle glycémique | PainNorvège
-
Ege UniversityComplétéObésité | Index glycémique | Glucose sanguin | PainTurquie
-
PfizerComplétéLeucémie, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) PositifFrance, États-Unis, Canada, Espagne, Tchéquie, Singapour, Thaïlande, Danemark, Norvège, Corée, République de, Finlande, Hongrie, Suède, Pays-Bas, Italie, Allemagne, Ukraine, Afrique du Sud, Taïwan, Australie, Belgique, Israël, Mexique, Pologn... et plus
Essais cliniques sur Cognitive Behavioral Therapy
-
Norwegian Center for Violence and Traumatic Stress...King's College London; University of Oslo; Ministry of Health and Care Services...RecrutementSSPT | Qualité de vie | Troubles du sommeil | Symptômes dépressifsNorvège
-
VA Office of Research and DevelopmentComplétéTroubles de stress, post-traumatiqueÉtats-Unis
-
Weill Medical College of Cornell UniversityRecrutementDépression périnatale | Anxiété périnataleÉtats-Unis
-
University of WashingtonNational Institute on Drug Abuse (NIDA)ComplétéTroubles liés à l'utilisation de substances | Troubles de stress post-traumatique | Sexe à risqueÉtats-Unis
-
Medical University of South CarolinaNational Institute on Deafness and Other Communication Disorders (NIDCD)RecrutementAccident vasculaire cérébral | Aphasie | Aphasie Non FluentÉtats-Unis
-
Columbia UniversityRésilié
-
NeuroTronik Inc.InconnueInsuffisance cardiaque | Insuffisance cardiaque aiguëParaguay
-
Microclinic InternationalRoyal Health Awareness Society (RHAS); Jordanian Ministry of Health (MoH)ComplétéHyperglycémie | Hypertension | Obésité | Diabète sucré, Type 2 | Diabète sucré | Diabète | Poids | Perte de poids | Pression artérielle | Gain de poids | Comportement social | Poids, Corps | Glycémie, hypertension | Mode de vie, Sain | Changement de poids, Corps | Comportement, Santé | Réduction des risques liés au mode... et d'autres conditionsJordan
-
NeuroTronik Inc.InconnueInsuffisance cardiaque aiguëPanama
-
University of Applied Sciences and Arts of Southern...Vrije Universiteit Brussel; Universiteit Antwerpen; THIM - die internationale...ComplétéEn bonne santéSuisse